Compare CABO & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABO | CSTL |
|---|---|---|
| Founded | 1980 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.1M | 661.7M |
| IPO Year | N/A | 2019 |
| Metric | CABO | CSTL |
|---|---|---|
| Price | $120.50 | $39.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $126.00 | $38.67 |
| AVG Volume (30 Days) | 153.0K | ★ 531.8K |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | ★ 4.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,524,897,000.00 | $343,530,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.15 |
| 52 Week Low | $96.67 | $14.59 |
| 52 Week High | $428.14 | $40.61 |
| Indicator | CABO | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 78.03 |
| Support Level | $96.67 | $38.64 |
| Resistance Level | $109.85 | $40.61 |
| Average True Range (ATR) | 7.24 | 1.45 |
| MACD | 2.82 | 0.11 |
| Stochastic Oscillator | 84.03 | 80.79 |
Cable One Inc. is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. From a product standpoint, the majority of revenue comes from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols. Cable One Inc. owns its telecommunications infrastructure.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.